Infusion reactions to monoclonal antibodies for solid tumors: immunologic mechanisms and risk factors.
The development of monoclonal antibodies targeting various receptors and ligands has been a significant advance in cancer therapy. These monoclonal antibodies are generally well tolerated. A subset of patients, however, experience infusion reactions with symptoms ranging from mild to life-threatening anaphylaxis. The underlying mechanisms of these reactions are not well characterized. In this review, current findings in clinical risk factor assessments and known mechanisms of these infusion reactions are discussed.
Chung
Christine H
CH
Division of Hematology/Oncology, Department of Medicine, Vanderbilt University, School of Medicine, Nashville, Tennessee, USA.
O'Neil
Bert H
BH
D000707:Anaphylaxis / Q000139:chemically induced*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology; D004342:Drug Hypersensitivity / Q000209:etiology*; D006801:Humans; D007262:Infusions, Intravenous; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D012307:Risk Factors
D000911:Antibodies, Monoclonal